Witha focus on changing the way transplant medicine is practiced, Triursus Therapeutics Incorporated is addressing transformations in the way patients with serious hematologic malignancies are treated. Despite the best current care, many patients undergoing a potentially curative transplant develop GVHD - a condition with a high rate of morbidity and mortality. Describing this as a "high unmet need" , principals of Triursus Therapeutics Incorporated are organized around leveraging on their valued insights on disease biology and pathophysiology to develop potential therapeutics. Addressing potential treatment of serious inflammatory diseases - enabling reductions in rates of morbidity and mortality.among patients - Triursus Therapeutics Incorporated is a biotech company developing novel monoclonal antibodies against several targets: inflammatory bowel disease (IBD), Crohn disease and ulcerative colitis, graft-versus-host disease (GVHD)
